OncoMatch/Clinical Trials/NCT04540107
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Is NCT04540107 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Hyperpolarized Carbon C 13 Pyruvate for recurrent world health organization (who) grade ii glioma.
Treatment: Hyperpolarized Carbon C 13 Pyruvate — This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage II, III (WHO)
Grade: IIIII (WHO)
WHO Grade II Glioma; WHO Grade III Glioma
Lab requirements
Kidney function
creatinine < 1.5 mg/dL before imaging
Cardiac function
No NYHA grade II or greater congestive heart failure; no history of myocardial infarction or unstable angina within 12 months prior to study enrollment
adequate renal function (creatinine < 1.5 mg/dL) before imaging ... must not have NYHA grade II or greater congestive heart failure ... must not have history of myocardial infarction or unstable angina within 12 months prior to study enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Francisco · San Francisco, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify